- Home
- PCVX vs LAZ Comparison
PCVX vs LAZ Comparison
Compare PCVX & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- LAZ
- Stock Information
- Founded
- PCVX 2013
- LAZ 1848
- Country
- PCVX United States
- LAZ United States
- Employees
- PCVX N/A
- LAZ N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- LAZ Investment Managers
- Sector
- PCVX Health Care
- LAZ Finance
- Exchange
- PCVX Nasdaq
- LAZ Nasdaq
- Market Cap
- PCVX 4.4B
- LAZ 4.0B
- IPO Year
- PCVX 2020
- LAZ 2005
- Fundamental
- Price
- PCVX $32.94
- LAZ $48.37
- Analyst Decision
- PCVX Strong Buy
- LAZ Hold
- Analyst Count
- PCVX 10
- LAZ 7
- Target Price
- PCVX $136.50
- LAZ $46.33
- AVG Volume (30 Days)
- PCVX 1.5M
- LAZ 902.9K
- Earning Date
- PCVX 08-05-2025
- LAZ 07-24-2025
- Dividend Yield
- PCVX N/A
- LAZ 4.18%
- EPS Growth
- PCVX N/A
- LAZ N/A
- EPS
- PCVX N/A
- LAZ 2.87
- Revenue
- PCVX N/A
- LAZ $2,939,019,000.00
- Revenue This Year
- PCVX N/A
- LAZ N/A
- Revenue Next Year
- PCVX N/A
- LAZ $14.45
- P/E Ratio
- PCVX N/A
- LAZ $16.65
- Revenue Growth
- PCVX N/A
- LAZ 7.18
- 52 Week Low
- PCVX $27.66
- LAZ $31.97
- 52 Week High
- PCVX $121.06
- LAZ $61.14
- Technical
- Relative Strength Index (RSI)
- PCVX 46.08
- LAZ 65.85
- Support Level
- PCVX $32.06
- LAZ $45.92
- Resistance Level
- PCVX $33.81
- LAZ $44.27
- Average True Range (ATR)
- PCVX 1.23
- LAZ 1.33
- MACD
- PCVX -0.12
- LAZ 0.39
- Stochastic Oscillator
- PCVX 19.86
- LAZ 85.07
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About LAZ Lazard Inc.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.